Japan approves IMCIVREE for acquired hypothalamic obesity, expanding Rhythm Pharmaceuticals’ global franchise. See what the approval means for growth.
Rhythm Pharmaceuticals has reported preliminary RM-718 data showing an 11.6% mean body mass index reduction after 16 weeks in seven patients with acquired hypothalamic obesity. The small, open-label dataset supports further development but cannot yet establish how the weekly injection compares with approved daily setmelanotide.
Rhythm Pharmaceuticals reports an 11.6% BMI reduction with weekly RM-718 in a small hypothalamic obesity study. See what the data reveal.